The vitruvias therapeutics thyroid recall fda update has become a significant medication safety story after the FDA classified the recalled thyroid tablets as a Class I recall. The recall involves one lot of Vitruvias Therapeutics Thyroid Tablets, USP 30 mg that testing found could be superpotent.
Vitruvias Therapeutics announced the voluntary recall on August 21, 2026.
The FDA published the company’s recall notice on August 24.
The affected product is Thyroid Tablets, USP 30 mg, from Lot 504950.
The product carries NDC 69680-166-00.
Its listed expiration date is September 30, 2026.
The affected lot was distributed nationwide in the United States.
Distribution occurred between January 31, 2025, and September 30, 2025.
Vitruvias released 3,655 units from the affected lot.
The company reported that 1,955 units were sold.
The recall concerns potential superpotency.
A superpotent thyroid tablet can contain more thyroid hormone than intended.
That can increase the risk of hyperthyroidism, or an overactive thyroid.
The FDA’s Class I classification makes the latest update especially important for people who may still have the recalled medication.
Patients who identify the affected lot should contact their healthcare provider or pharmacist for instructions.
They should not independently change or stop prescribed thyroid treatment without medical guidance.
What Triggered the Vitruvias Thyroid Recall?
Vitruvias recalled one lot of its Thyroid Tablets, USP 30 mg after testing confirmed the potential for superpotency.
The issue concerns the strength of the medication.
Thyroid replacement treatment depends on consistent dosing.
Patients with hypothyroidism receive thyroid hormone because their bodies do not produce enough.
If a tablet contains more hormone than intended, a patient may receive excessive thyroid hormone.
That can push the body toward hyperthyroidism.
The company therefore initiated a voluntary recall at the consumer level.
The recall covers Lot 504950 rather than every Vitruvias thyroid product.
Patients should check their medication packaging before assuming they are affected.
Which Vitruvias Thyroid Tablets Are Recalled?
The FDA recall concerns one specific product and one specific lot.
Patients can compare their medication with the following information:
| Recall detail | Information |
|---|---|
| Product | Thyroid Tablets, USP 30 mg |
| Manufacturer | Vitruvias Therapeutics, Inc. |
| NDC | 69680-166-00 |
| Lot number | 504950 |
| Expiration date | September 30, 2026 |
| Units released | 3,655 |
| Units sold | 1,955 |
| First distribution | January 31, 2025 |
| Last distribution | September 30, 2025 |
| Distribution | Nationwide in the United States |
The lot number is one of the most important details.
Patients should look for 504950 on their medication packaging.
The NDC, product description and expiration date provide additional confirmation.
A different lot number does not match the specific recalled lot.
What Does Superpotent Thyroid Medication Mean?
Superpotent medication contains more active drug than intended.
In this case, the concern involves thyroid hormones.
Thyroid Tablets, USP is a natural thyroid preparation derived from porcine thyroid glands.
It contains levothyroxine, also called T4, and liothyronine, also called T3.
Both hormones affect the body’s metabolism and other physiological functions.
Patients taking thyroid replacement medication need an appropriate dose.
An excessive amount can increase thyroid hormone activity.
That can produce symptoms associated with an overactive thyroid.
The potential consequences explain why the FDA and manufacturer issued the recall.
What Is Hyperthyroidism?
Hyperthyroidism occurs when the body has too much thyroid hormone activity.
It can affect the cardiovascular system, nervous system and metabolism.
The FDA recall information lists several possible symptoms associated with excessive thyroid hormone exposure.
These include:
- Weight loss
- Heat intolerance
- Fatigue
- Nervousness
- Muscle weakness
- High blood pressure
- Chest pain
- Rapid heart rate
- Heart rhythm disturbances
The presence of one of these symptoms does not establish that the recalled medication caused it.
Many medical conditions can produce similar symptoms.
Patients who take the recalled product and develop concerning symptoms should discuss them with a healthcare professional.
Severe symptoms, including chest pain or serious heart-related symptoms, require prompt medical attention.
Why Did the FDA Classify It as Class I?
The FDA uses recall classifications to communicate the relative level of health hazard associated with a recalled product.
Class I is the highest classification.
The FDA defines a Class I recall as a situation where there is a reasonable probability that use of or exposure to the violative product could cause serious adverse health consequences or death.
That classification does not mean that every patient who used the recalled medication will experience serious harm.
It describes the potential level of risk associated with the recalled product.
The Vitruvias recall involves a potential potency problem.
Excessive thyroid hormone exposure can produce significant medical effects.
The Class I classification reflects the seriousness of that potential risk.
When Did Vitruvias Announce the Recall?
Vitruvias Therapeutics announced the voluntary recall on August 21, 2026.
The FDA published the company’s announcement on August 24.
The original recall covered one lot of Thyroid Tablets, USP 30 mg.
Testing had confirmed the potential for the product to be superpotent.
The company notified wholesalers by email and phone.
It also began arrangements to destroy recalled product.
The recall was conducted with FDA knowledge.
The September classification provided the latest major regulatory update.
What Changed With the September FDA Update?
The key development in September was the FDA’s classification of the recall as Class I.
The original August announcement already identified the potential superpotency problem.
The later classification established the FDA’s highest recall-risk designation.
The underlying issue did not change.
The concern remains the possibility that the affected tablets could provide excessive thyroid hormone.
Patients should therefore continue to use the lot number and product information when determining whether their medication is affected.
The classification does not mean every thyroid medication from Vitruvias is recalled.
It applies to the specific recalled product and lot.
How Many Tablets Were Involved?
Vitruvias released 3,655 units from Lot 504950.
The company reported that 1,955 units were sold.
The affected products were distributed nationwide.
The distribution period ran from January 31 through September 30, 2025.
That broad distribution means the recall is not limited to one state or region.
Patients across the United States could have received the affected lot.
Checking the medication packaging remains the most useful way to determine whether a patient’s product matches the recall.
Was the Recall Nationwide?
Yes.
Lot 504950 was distributed nationwide through Vitruvias Therapeutics’ direct accounts.
The first distribution date was January 31, 2025.
The last distribution date was September 30, 2025.
The nationwide distribution means consumers should not rely on location when checking for the recall.
A patient living in any U.S. state could potentially have received the affected product.
The product’s NDC, lot number and expiration date provide more specific identification.
Who May Face Greater Risk?
The FDA recall information identifies several groups as having greater risk from superpotent thyroid medication.
Those groups include:
- Older adults
- Pregnant women
- Infants
The concern becomes particularly important with prolonged exposure.
Older adults may face greater cardiovascular risks from excessive thyroid hormone levels.
Pregnancy also requires careful management of thyroid hormone replacement.
The FDA notes that overtreatment during pregnancy is associated with maternal and fetal complications, including premature delivery and low birth weight.
Infants also require carefully controlled thyroid hormone levels.
Overtreatment may negatively affect growth and development.
These risks demonstrate why thyroid medication potency matters.
What Should Patients Do If They Have Lot 504950?
Patients who discover that they have Lot 504950 should contact their healthcare provider or pharmacist.
They should provide the product name, strength and lot number.
The recalled product is Thyroid Tablets, USP 30 mg.
The NDC is 69680-166-00.
The lot is 504950.
The expiration date is September 30, 2026.
Patients should keep their medication packaging available when speaking with a healthcare professional.
That makes product identification easier.
A pharmacist can also help determine whether the medication belongs to the recalled lot.
Should Patients Stop Taking the Recalled Thyroid Tablets?
Patients should not stop their thyroid medication on their own.
The FDA recall notice specifically advises patients taking Thyroid, USP from Lot 504950 to contact their healthcare provider before discontinuing use.
A doctor can provide guidance and arrange a replacement prescription when appropriate.
Thyroid hormone treatment requires consistent management.
Suddenly stopping therapy can cause thyroid hormone levels to fall.
That can worsen hypothyroidism.
The correct response to the recall depends on the individual patient.
Patients should therefore contact their doctor or pharmacist promptly after identifying the affected lot.
What Symptoms Could Result From Excess Thyroid Hormone?
Excess thyroid hormone can produce symptoms associated with hyperthyroidism.
Potential symptoms include rapid heart rate and nervousness.
Some people may experience heat intolerance.
Weight loss and muscle weakness can also occur.
Fatigue is another possible symptom.
High blood pressure can develop.
More serious cardiovascular effects may include chest pain or heart rhythm disturbances.
Patients should not assume that every symptom represents a medication problem.
However, anyone taking the recalled lot should tell their healthcare provider about new or concerning symptoms.
Emergency symptoms require immediate medical evaluation.
Why Can Too Much Thyroid Hormone Be Dangerous?
Thyroid hormones affect many organs and body systems.
They influence metabolism, energy use and cardiovascular function.
An excessive amount can place additional stress on the heart.
It can also produce symptoms involving the nervous system and muscles.
The risk can become more significant in vulnerable populations.
Older adults may face particular cardiovascular concerns.
Pregnant women require careful thyroid management because both insufficient and excessive thyroid hormone can create problems.
Infants also need appropriate thyroid hormone levels for normal development.
That is why the potency of thyroid replacement medication matters.
What Is Thyroid, USP?
Thyroid, USP is a natural thyroid preparation.
The Vitruvias product is derived from porcine thyroid glands.
It contains two primary thyroid hormones.
These are levothyroxine, or T4, and liothyronine, or T3.
The medication is used for thyroid hormone replacement in people with hypothyroidism.
Hypothyroidism occurs when the thyroid does not produce enough thyroid hormone.
Replacement therapy aims to provide the hormones the body lacks.
The dose must remain appropriate for the patient.
A product with excessive potency can disrupt that balance.
Is This Recall for All Thyroid Medicines?
No.
The Vitruvias recall does not apply to every thyroid medication sold in the United States.
It concerns one specific Vitruvias product and one specific lot.
The affected product is Thyroid Tablets, USP 30 mg.
The NDC is 69680-166-00.
The lot is 504950.
The expiration date is September 30, 2026.
Patients taking a different thyroid medication should not assume it belongs to this recall.
Other thyroid medicines may have different manufacturers, strengths, formulations and lot numbers.
A pharmacist can confirm whether a specific prescription is affected.
Did Vitruvias Report Adverse Events?
At the time of the original recall announcement, Vitruvias stated that it had not received reports of adverse events known to be related to the recall.
That statement appeared in the August recall information.
The absence of reported events does not remove the potential safety concern.
The recall was initiated because testing confirmed the potential for superpotency.
Patients who experience suspected adverse reactions should contact their healthcare provider.
They can also report medication-related problems through the FDA’s MedWatch program.
How Can Consumers Report Side Effects?
The FDA operates the MedWatch Adverse Event Reporting Program.
Patients and healthcare professionals can use the program to report suspected adverse reactions and product-quality problems.
Consumers should provide as much information as possible.
Useful details include:
- Product name
- Strength
- Lot number
- Expiration date
- Symptoms
- Approximate dates of use
- Relevant medical information
For the recalled Vitruvias product, Lot 504950 is the key identification detail.
Patients should also tell their healthcare provider about suspected reactions.
What Should Pharmacists Do?
Pharmacists can help patients identify whether their medication belongs to the recalled lot.
They can check the product’s NDC and lot information.
The affected NDC is 69680-166-00.
The affected lot is 504950.
Pharmacists can also communicate with prescribers when patients need alternative medication.
Patients should bring the original bottle or packaging when possible.
That can help avoid confusion between different thyroid products.
What Happened to Vitruvias Therapeutics?
Vitruvias Therapeutics has also undergone a significant business change.
The company’s website states that Vitruvias has ceased operations.
The website says its products are now owned and distributed by H2-Pharma LLC.
This development occurred around the same period as the thyroid recall.
The change in company operations does not cancel or alter the recall.
The affected lot remains the subject of the FDA safety action.
Patients seeking assistance should use current information from their pharmacist, healthcare provider or relevant regulatory information.
What Is the Current Status of Lot 504950?
As of September 24, 2026, Lot 504950 remains the affected lot in the Vitruvias thyroid recall.
The product is Thyroid Tablets, USP 30 mg.
The NDC is 69680-166-00.
The expiration date is September 30, 2026.
The FDA has classified the recall as Class I.
The product was distributed nationwide.
Vitruvias previously instructed wholesalers to stop distributing the affected product and arranged for recalled inventory to be destroyed.
Patients who still have the product should contact their healthcare provider or pharmacist.
Important Recall Details at a Glance
For readers who want to check their medication quickly, the key information is:
Product: Thyroid Tablets, USP 30 mg
Manufacturer: Vitruvias Therapeutics, Inc.
NDC: 69680-166-00
Lot: 504950
Expiration: September 30, 2026
Recall reason: Potential superpotency
Distribution: Nationwide in the United States
Units released: 3,655
Units sold: 1,955
First distribution: January 31, 2025
Last distribution: September 30, 2025
FDA classification: Class I
What Makes This Recall Different From a Subpotency Recall?
Potency problems can occur in either direction.
A subpotent medication contains less active ingredient than intended.
A superpotent medication can contain more.
The Vitruvias recall concerns potential superpotency.
That means the concern is excessive thyroid hormone exposure.
For thyroid replacement treatment, both underdosing and overdosing can create medical problems.
Patients therefore should not change their medication dose themselves.
A healthcare professional should determine the appropriate replacement and treatment plan.
What Should Patients Remember About the Recall?
The most important point is that the recall applies to a specific lot.
Patients should look for Lot 504950.
They should also confirm the product name and NDC.
The affected medication is Thyroid Tablets, USP 30 mg.
The NDC is 69680-166-00.
The product may be superpotent.
That can cause excessive thyroid hormone exposure and symptoms associated with hyperthyroidism.
Patients should contact their healthcare provider before stopping the recalled medication.
They should also seek medical attention for serious or concerning symptoms.
Vitruvias Therapeutics Thyroid Recall FDA: Latest September 2026 Update
The vitruvias therapeutics thyroid recall fda situation remains important for U.S. patients who may have received Thyroid Tablets, USP 30 mg from Lot 504950.
Vitruvias initiated the voluntary recall on August 21, 2026.
The FDA published the recall announcement on August 24.
The reason was potential superpotency confirmed through testing.
The affected product carries NDC 69680-166-00.
The lot number is 504950.
The expiration date is September 30, 2026.
The company released 3,655 units and reported that 1,955 were sold.
The affected lot was distributed nationwide between January 31 and September 30, 2025.
The FDA later classified the recall as Class I, its highest recall classification.
The concern involves the potential for excessive thyroid hormone exposure.
That exposure can cause hyperthyroidism and symptoms such as weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and heart rhythm disturbances.
Older adults, pregnant women and infants face greater risks, particularly with prolonged exposure.
Patients who identify Lot 504950 should contact their healthcare provider or pharmacist for guidance.
They should not independently stop or change prescribed thyroid treatment.
The current company status also matters. Vitruvias Therapeutics has stated that it has ceased operations and that its products are now owned and distributed by H2-Pharma LLC.
For consumers, the most important step remains checking the medication packaging for the recalled lot and seeking professional guidance if it matches.
Do you have the recalled Vitruvias thyroid tablets or questions about Lot 504950? Share your thoughts in the comments and stay updated on the latest FDA medication safety news.